-
Nutriband responds to fentanyl weapon of mass destruction designation
-
Nutriband Inc. To Present at The 2025 Noble Capital Markets Emerging Growth Equity Conference
-
Nutriband receives FDA feedback on abuse deterrent fentanyl patch
-
Nutriband co-founder Gareth Sheridan returns as CEO
-
Nutriband partners with Brand Institute for fentanyl patch naming
-
Nutriband files provisional patent for enhanced abuse deterrent technology
-
Nutriband reports 50.87% revenue increase in first half of 2025
-
FDA approves meeting request for Nutriband's fentanyl patch development
-
Nutriband sets dates for 25% preferred stock dividend
-
Nutriband (NTRB) Announces 25% Preferred Stock Dividend as it targets filing for FDA approval
-
Nutriband (NTRB) Announces U.S. Patent Issued for Its Transdermal Abuse Deterrent Technology
-
Nutriband (NTRB) CEO Publishes Letter to Shareholders
-
Nutriband (NTRB) Granted Patent in Macao for its AVERSA Abuse Deterrent Transdermal Technology
-
Nutriband (NTRB) Signs Partnership Agreement with Charlotte FC
-
Nutriband (NTRB) Receives Certificate of Registration for Trademark covering Pharmaceutical and Product Research and Development.
-
Nutriband (NTRB) and Kindeva Drug Delivery Formalize Exclusive Development Partnership for Aversa™ Fentanyl Abuse Deterrent Fentanyl Patch
-
NutriBand (NTRB) secures patent for abuse deterrent technology
-
Nutriband (NTRB) Receives Notice Of Allowance For New U.S. Patent Covering Its Transdermal Abuse Deterrent Technology Aversa
-
Noble Capital Starts Nutriband (NTRB) at Outperform
-
Nutriband (NTRB) Issues Letter to Shareholders
-
Nutriband (NTRB) Extends Chinese Patent to Macao for its AVERSA Abuse Deterrent Transdermal Technology
-
Nutriband (NTRB) Receives Hong Kong Patent Notice of Publication for Its Aversa Abuse Deterrent Transdermal Technology
-
Nutriband Inc. Issued Full Patent from the Chinese National Intellectual Property Administrant for Its "Abuse and Misuse Deterrent Transdermal System" Application
-
Nutriband Inc Mosquito Repellent Patch Approved by Ministry of Health of Costa Rica
-
Join Nutriband's Exclusive Live Investor Webinar and Q&A Session on October 17
-
Nutriband (NTRB) Receives China Patent Notice of Allowance for Aversa Abuse Deterrent Transdermal Technology
-
Nutriband Receives China Patent Notice of Allowance for Its Aversa(TM) Abuse Deterrent Transdermal Technology
-
Nutriband (NTRB) Licenses Bitrex Brand Aversive Agent for Its Lead Product
-
Nutriband Licenses Bitrex(R) Brand Aversive Agent for Its Lead Product - Aversa(TM) Fentanyl Transdermal Patch
-
Nutriband (NTRB) Announces $1M Share Buyback
-
Nutriband Inc. Authorizes $1M Share Buyback Program
-
Nutriband Inc. Quarterly Report Highlights Strong Cash Position, and Strategic Progress Toward NDA Filing for AVERSA Fentanyl in 2025
-
Join Nutriband's Exclusive Live Investor Webinar and Q&A Session on July 25
-
Nutriband (NTRB) Receives Notice of Allowance for U.S. Trademark Covering AVERSA Abuse Deterrent Technology
-
Nutriband Receives Notice of Allowance for U.S. Trademark Covering AVERSA(TM) Abuse Deterrent Technology
-
Nutriband (NTRB) Provides Product Development Update for Aversa Fentanyl
-
Nutriband Provides Product Development Update for Its Lead Product Aversa Fentanyl

